Biased mGlu5-Positive Allosteric Modulators Provide InVivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents

Neuron

Volumn 86, Issue 4, 2015, Pages 1029-1040

  Rook, Jerri M ^a   Xiang, Zixiu ^a   Lv, Xiaohui ^a   Ghoshal, Ayan ^a   Dickerson, Jonathan W ^a   Bridges, Thomas M ^a   Johnson, Kari A ^a   Foster, Daniel J ^a   Gregory, Karen J ^a,b   Vinson, Paige N ^a   Thompson, Analisa D ^a   Byun, Nellie ^a   Collier, Rebekah L ^a   Bubser, Michael ^a   Nedelcovych, Michael T ^a   Gould, Robert W ^a   Stauffer, Shaun R ^a   Daniels, J Scott ^a   Niswender, Colleen M ^a   Lavreysen, Hilde ^c   Mackie, Claire ^c   Conde Ceide, Susana ^c   Alcazar, Jesus ^c   Bartolomé Nebreda, José M ^c   Macdonald, Gregor J ^c   Talpos, John C ^c   Steckler, Thomas ^c   Jones, Carrie K ^a   Lindsley, Craig W ^a   Conn, P Jeffrey ^a   more..

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MONASH UNIVERSITY   (Australia)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; POSITIVE ALLOSTERIC MODULATOR; UNCLASSIFIED DRUG; VU0409551; GLUTAMIC ACID;

ALLOSTERISM; ANIMAL CELL; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; CALCIUM MOBILIZATION; COGNITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENDRITIC CELL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG TRANSFORMATION; ELECTRIC POTENTIAL; ENZYME PHOSPHORYLATION; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL; LOCOMOTION; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MALE; MAXIMUM PLASMA CONCENTRATION; NERVE CELL PLASTICITY; NEUROMODULATION; NONHUMAN; NONREM SLEEP; PATCH CLAMP TECHNIQUE; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REM SLEEP; SCHAFFER COLLATERAL PATHWAY; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SLEEP WAKING CYCLE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ALLOSTERIC REGULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; COGNITION; GLUTAMIC ACID; HEK293 CELLS; HIPPOCAMPUS; HUMANS; MALE; RATS, SPRAGUE-DAWLEY; RECEPTOR, METABOTROPIC GLUTAMATE 5; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION;

EID: 84930274249     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2015.03.063     Document Type: Article

References (56)

1. Awad H., Hubert G.W., Smith Y., Levey A.I., Conn P.J. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J.Neurosci. 2000, 20:7871-7879.
2. Ayala J.E., Chen Y., Banko J.L., Sheffler D.J., Williams R., Telk A.N., Watson N.L., Xiang Z., Zhang Y., Jones P.J., et al. mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology 2009, 34:2057-2071.
3. Ben-Ari Y., Aniksztejn L., Bregestovski P. Protein kinase C modulation of NMDA currents: an important link for LTP induction. Trends Neurosci. 1992, 15:333-339.
4. Bridges T.M., Rook J.M., Noetzel M.J., Morrison R.D., Zhou Y., Gogliotti R.D., Vinson P.N., Xiang Z., Jones C.K., Niswender C.M., et al. Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism. Drug Metab. Dispos. 2013, 41:1703-1714.
5. Brody S.A., Conquet F., Geyer M.A. Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology (Berl.) 2004, 172:187-195.
6. Campbell U.C., Lalwani K., Hernandez L., Kinney G.G., Conn P.J., Bristow L.J. The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine(MPEP) potentiates PCP-induced cognitive deficits in rats. Psychopharmacology (Berl.) 2004, 175:310-318.
7. Collingridge G.L., Kehl S.J., McLennan H. Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat hippocampus. J.Physiol. 1983, 334:33-46.
8. Collingridge G.L., Volianskis A., Bannister N., France G., Hanna L., Mercier M., Tidball P., Fang G., Irvine M.W., Costa B.M., et al. The NMDA receptor as a target for cognitive enhancement. Neuropharmacology 2013, 64:13-26.
9. Conn P.J., Lindsley C.W., Meiler J., Niswender C.M. Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat. Rev. Drug Discov. 2014, 13:692-708.
10. Coyle J.T., Basu A., Benneyworth M., Balu D., Konopaske G. Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Handbook Exp. Pharmacol. 2012, 213:267-295.
11. Croy C.H., Schober D.A., Xiao H., Quets A., Christopoulos A., Felder C.C. Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M(2) and M(4) receptors. Mol. Pharmacol. 2014, 86:106-115.
12. Darrah J.M., Stefani M.R., Moghaddam B. Interaction of N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm. Behav. Pharmacol. 2008, 19:225-234.
13. Doherty A.J., Palmer M.J., Henley J.M., Collingridge G.L., Jane D.E. (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 1997, 36:265-267.
14. Field J.R., Walker A.G., Conn P.J. Targeting glutamate synapses in schizophrenia. Trends Mol. Med. 2011, 17:689-698.
15. Fitzjohn S.M., Irving A.J., Palmer M.J., Harvey J., Lodge D., Collingridge G.L. Activation of group I mGluRs potentiates NMDA responses in rat hippocampal slices. Neurosci. Lett. 1996, 203:211-213.
16. França A.S., do Nascimento G.C., Lopes-dos-Santos V., Muratori L., Ribeiro S., Lobão-Soares B., Tort A.B. Beta2 oscillations (23-30Hz) in the mouse hippocampus during novel object recognition. Eur. J. Neurosci. 2014, 40:3693-3703.
17. Gao C., Tronson N.C., Radulovic J. Modulation of behavior byscaffolding proteins of the post-synaptic density. Neurobiol. Learn. Mem. 2013, 105:3-12.
18. 5 positive allosteric modulator LSN2463359 differentially modulates motor, instrumental and cognitive effects of NMDA receptor antagonists in the rat. Neuropharmacology 2013, 64:240-247.
19. 5 receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology 2013, 64:224-239.
20. Gregory K.J., Noetzel M.J., Rook J.M., Vinson P.N., Stauffer S.R., Rodriguez A.L., Emmitte K.A., Zhou Y., Chun A.C., Felts A.S., et al. Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships. Mol. Pharmacol. 2012, 82:860-875.
21. Gregory K.J., Herman E.J., Ramsey A.J., Hammond A.S., Byun N.E., Stauffer S.R., Manka J.T., Jadhav S., Bridges T.M., Weaver C.D., et al. N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement. J.Pharmacol. Exp. Ther. 2013, 347:438-457.
22. 5) positive allosteric modulator (PAM) binding pocket: discovery of point mutations that engender a "molecular switch" in PAM pharmacology. Mol. Pharmacol. 2013, 83:991-1006.
23. Hammond A.S., Rodriguez A.L., Townsend S.D., Niswender C.M., Gregory K.J., Lindsley C.W., Conn P.J. Discovery of a Novel Chemical Class of mGlu(5) Allosteric Ligands with Distinct Modes of Pharmacology. ACS Chem. Neurosci. 2010, 1:702-716.
24. Harris E.W., Ganong A.H., Cotman C.W. Long-term potentiation in the hippocampus involves activation of N-methyl-D-aspartate receptors. Brain Res. 1984, 323:132-137.
25. Henry S.A., Lehmann-Masten V., Gasparini F., Geyer M.A., Markou A. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 2002, 43:1199-1209.
26. Homayoun H., Stefani M.R., Adams B.W., Tamagan G.D., Moghaddam B. Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release. Neuropsychopharmacology 2004, 29:1259-1269.
27. Hu J.H., Yang L., Kammermeier P.J., Moore C.G., Brakeman P.R., Tu J., Yu S., Petralia R.S., Li Z., Zhang P.W., et al. Preso1 dynamically regulates group I metabotropic glutamate receptors. Nat. Neurosci. 2012, 15:836-844.
28. Huber K.M., Roder J.C., Bear M.F. Chemical induction of mGluR5- and protein synthesis-dependent long-term depression in hippocampal area CA1. J.Neurophysiol. 2001, 86:321-325.
29. Jones C.K., Bubser M., Thompson A.D., Dickerson J.W., Turle-Lorenzo N., Amalric M., Blobaum A.L., Bridges T.M., Morrison R.D., Jadhav S., et al. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. J.Pharmacol. Exp. Ther. 2012, 340:404-421.
30. Kinney G.G., Burno M., Campbell U.C., Hernandez L.M., Rodriguez D., Bristow L.J., Conn P.J. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J.Pharmacol. Exp. Ther. 2003, 306:116-123.
31. Kinney G.G., O'Brien J.A., Lemaire W., Burno M., Bickel D.J., Clements M.K., Chen T.B., Wisnoski D.D., Lindsley C.W., Tiller P.R., et al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has invivo activity and antipsychotic-like effects in rat behavioral models. J.Pharmacol. Exp. Ther. 2005, 313:199-206.
32. Lebois E.P., Bridges T.M., Lewis L.M., Dawson E.S., Kane A.S., Xiang Z., Jadhav S.B., Yin H., Kennedy J.P., Meiler J., et al. Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. ACS Chem. Neurosci. 2010, 1:104-121.
33. Liu F., Grauer S., Kelley C., Navarra R., Graf R., Zhang G., Atkinson P.J., Popiolek M., Wantuch C., Khawaja X., et al. ADX47273 [S-(4-fluoro-phenyl)-3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J.Pharmacol. Exp. Ther. 2008, 327:827-839.
34. Mannaioni G., Marino M.J., Valenti O., Traynelis S.F., Conn P.J. Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J.Neurosci. 2001, 21:5925-5934.
35. Maren S., Holt W. The hippocampus and contextual memory retrieval in Pavlovian conditioning. Behav. Brain Res. 2000, 110:97-108.
36. Marino M.J., Conn P.J. Direct and indirect modulation of the N-methyl D-aspartate receptor. Curr. Drug Targets CNS Neurol. Disord. 2002, 1:1-16.
37. Matosin N., Newell K.A. Metabotropic glutamate receptor 5 in thepathology and treatment of schizophrenia. Neurosci. Biobehav. Rev. 2013, 37:256-268.
38. Müller L., Tokay T., Porath K., Köhling R., Kirschstein T. Enhanced NMDA receptor-dependent LTP in the epileptic CA1 area via upregulation of NR2B. Neurobiol. Dis. 2013, 54:183-193.
39. Niswender C.M., Conn P.J. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 2010, 50:295-322.
40. Niswender C.M., Johnson K.A., Luo Q., Ayala J.E., Kim C., Conn P.J., Weaver C.D. A novel assay of Gi/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors. Mol. Pharmacol. 2008, 73:1213-1224.
41. Noetzel M.J., Rook J.M., Vinson P.N., Cho H.P., Days E., Zhou Y., Rodriguez A.L., Lavreysen H., Stauffer S.R., Niswender C.M., et al. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Mol. Pharmacol. 2012, 81:120-133.
42. Noetzel M.J., Gregory K.J., Vinson P.N., Manka J.T., Stauffer S.R., Lindsley C.W., Niswender C.M., Xiang Z., Conn P.J. A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling. Mol. Pharmacol. 2013, 83:835-847.
43. O'Brien J.A., Lemaire W., Wittmann M., Jacobson M.A., Ha S.N., Wisnoski D.D., Lindsley C.W., Schaffhauser H.J., Rowe B., Sur C., et al. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J.Pharmacol. Exp. Ther. 2004, 309:568-577.
44. Park J.M., Hu J.H., Milshteyn A., Zhang P.W., Moore C.G., Park S., Datko M.C., Domingo R.D., Reyes C.M., Wang X.J., et al. A prolyl-isomerase mediates dopamine-dependent plasticity and cocaine motor sensitization. Cell 2013, 154:637-650.
45. Parmentier-Batteur S., O'Brien J.A., Doran S., Nguyen S.J., Flick R.B., Uslaner J.M., Chen H., Finger E.N., Williams T.M., Jacobson M.A., Hutson P.H. Differential effects of the mGluR5 positive allosteric modulator CDPPB in the cortex and striatum following repeated administration. Neuropharmacology 2012, 62:1453-1460.
46. Parmentier-Batteur S., Hutson P.H., Menzel K., Uslaner J.M., Mattson B.A., O'Brien J.A., Magliaro B.C., Forest T., Stump C.A., Tynebor R.M., et al. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators-development challenges for a promising novel antipsychotic target. Neuropharmacology 2014, 82:161-173.
47. Peavy R.D., Sorensen S.D., Conn P.J. Differential regulation of metabotropic glutamate receptor 5-mediated phosphoinositide hydrolysis and extracellular signal-regulated kinase responses by protein kinase C in cultured astrocytes. J.Neurochem. 2002, 83:110-118.
48. Rammes G., Palmer M., Eder M., Dodt H.U., Zieglgänsberger W., Collingridge G.L. Activation of mGlu receptors induces LTD without affecting postsynaptic sensitivity of CA1 neurons in rat hippocampal slices. J.Physiol. 2003, 546:455-460.
49. Rodriguez A.L., Grier M.D., Jones C.K., Herman E.J., Kane A.S., Smith R.L., Williams R., Zhou Y., Marlo J.E., Days E.L., et al. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and invivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol. Pharmacol. 2010, 78:1105-1123.
50. Rook J.M., Noetzel M.J., Pouliot W.A., Bridges T.M., Vinson P.N., Cho H.P., Zhou Y., Gogliotti R.D., Manka J.T., Gregory K.J., et al. Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in invivo activity. Biol. Psychiatry 2013, 73:501-509.
51. Schmued L.C., Albertson C., Slikker W. Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res. 1997, 751:37-46.
52. Sheffler D.J., Conn P.J. Allosteric potentiators of metabotropic glutamate receptor subtype 1a differentially modulate independent signaling pathways in baby hamster kidney cells. Neuropharmacology 2008, 55:419-427.
53. Shepherd J.D., Huganir R.L. The cell biology of synaptic plasticity: AMPA receptor trafficking. Annu. Rev. Cell Dev. Biol. 2007, 23:613-643.
54. Stone T.W., Burton N.R. NMDA receptors and ligands in the vertebrate CNS. Prog. Neurobiol. 1988, 30:333-368.
55. Timms A.E., Dorschner M.O., Wechsler J., Choi K.Y., Kirkwood R., Girirajan S., Baker C., Eichler E.E., Korvatska O., Roche K.W., et al. Support for the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families. JAMA Psychiatry 2013, 70:582-590.
56. Zhang Y., Rodriguez A.L., Conn P.J. Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J.Pharmacol. Exp. Ther. 2005, 315:1212-1219.